We are live on ! Find out more
FC

Finepoint Capital Portfolio holdings

AUM $1.95B
1-Year Est. Return 45.61%
This Fund
S&P 500
This Quarter Est. Return
+18.43%
1 Year Est. Return
+45.61%
3 Year Est. Return
+24.83%
5 Year Est. Return
+26.66%
10 Year Est. Return
–
AUM
$289M
AUM Growth
+$27.3M
Cap. Flow
+$4.73M
Cap. Flow %
1.64%
Top 10 Hldgs %
61.4%
Holding
42
New
4
Increased
2
Reduced
14
Closed
5

Top Buys

Rank Stock Value
1
MORF
Morphic Holding, Inc. Common Stock
MORF
+$15M
2
CLVT icon
Clarivate
CLVT
+$10.6M
3
BHC icon
Bausch Health
BHC
+$8.59M
4
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$8.13M
5
SLDB icon
Solid Biosciences
SLDB
+$2.66M

Top Sells

Rank Stock Value
1
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$17.6M
2
APLS
Apellis Pharmaceuticals
APLS
+$3.62M
3
ARVN icon
Arvinas
ARVN
+$2.08M
4
TVTX icon
Travere Therapeutics
TVTX
+$2.06M
5
RLAY icon
Relay Therapeutics
RLAY
+$1.8M

Sector Composition

Rank Sector Weight
1 Healthcare 95.42%
2 Technology 4.11%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
APLS
1
DELISTED
Apellis Pharmaceuticals
APLS
$22M 7.62%
241,690
-42,000
-15% -$3.62M
PRTA icon
2
Prothena Corp
PRTA
$453M
$21.7M 7.5%
317,300
-14,300
-4% -$922K
ACAD icon
3
Acadia Pharmaceuticals
ACAD
$4.38B
$20.3M 7.02%
846,953
-69,400
-8% -$1.54M
SAGE
4
DELISTED
Sage Therapeutics
SAGE
$16.8M 5.82%
357,765
-31,100
-8% -$1.55M
FOLD
5
DELISTED
Amicus Therapeutics
FOLD
$16.7M 5.76%
1,325,775
-134,400
-9% -$1.59M
LKFT
6
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.97B
$16.5M 5.72%
406,859
-37,800
-9% -$1.54M
MORF
7
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$16.5M 5.7%
+287,556
New +$15M
SWTX
8
DELISTED
SpringWorks Therapeutics
SWTX
$16M 5.52%
608,628
-5,603
-0.9% -$147K
CERE
9
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$15.7M 5.42%
492,545
-46,900
-9% -$1.44M
MLTX icon
10
MoonLake Immunotherapeutics
MLTX
$1.64B
$15.4M 5.33%
+302,000
New +$8.13M
CRNX icon
11
Crinetics Pharmaceuticals
CRNX
$8.88B
$14.4M 4.97%
797,527
-70,900
-8% -$1.41M
SRPT icon
12
Sarepta Therapeutics
SRPT
$1.82B
$14.4M 4.97%
125,457
+2,700
+2% +$348K
ASND icon
13
Ascendis Pharma A/S
ASND
$17.1B
$12.5M 4.32%
139,772
-16,300
-10% -$1.42M
CYTK icon
14
Cytokinetics
CYTK
$10.9B
$12M 4.17%
369,093
-44,700
-11% -$1.65M
CLVT icon
15
Clarivate
CLVT
$1.53B
$11.9M 4.11%
+1,247,406
New +$10.6M
TVTX icon
16
Travere Therapeutics
TVTX
$5.27B
$11.7M 4.05%
761,721
-113,500
-13% -$2.06M
ARVN icon
17
Arvinas
ARVN
$517M
$10.2M 3.53%
411,500
-80,800
-16% -$2.08M
BHC icon
18
Bausch Health
BHC
$1.8B
$9.32M 3.22%
+1,165,000
New +$8.59M
RLAY icon
19
Relay Therapeutics
RLAY
$4.34B
$8.81M 3.05%
701,570
-144,700
-17% -$1.8M
SLDB icon
20
Solid Biosciences
SLDB
$858M
$5.04M 1.74%
961,251
+472,394
+97% +$2.66M
AAC.WS
21
DELISTED
Ares Acquisition Corporation Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50
AAC.WS
$404K 0.14%
504,706
– –
BTWNW
22
DELISTED
Bridgetown Holdings Limited Warrants
BTWNW
$222K 0.08%
895,000
– –
CCV.WS
23
DELISTED
Churchill Capital Corp V Warrants, each exercisable for one share of Class A common stock at an exercise price of $11.50 per share
CCV.WS
$110K 0.04%
612,000
– –
CCVI.WS
24
DELISTED
Churchill Capital Corp VI Warrants, each exercisable for one share of Class A common stock at an exercise price of $11.50 per share
CCVI.WS
$97.2K 0.03%
540,000
– –
CLDI.WS
25
DELISTED
Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00
CLDI.WS
$85.2K 0.03%
655,200
– –
1
2

Similar funds

NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
WPC
Waters Parkerson & Co New Orleans, Louisiana $1.95B AUM 15.9% 1-Year Est. Return
SGAM
Smith Group Asset Management Dallas, Texas $1.96B AUM 43.61% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
BC
Blackhill Capital Morristown, New Jersey $1.94B AUM 18.09% 1-Year Est. Return
FFH
Fairfax Financial Holdings Toronto, Ontario, Canada $1.94B AUM 27.76% 1-Year Est. Return
NFG
Nations Financial Group Cedar Rapids, Iowa $1.94B AUM 25.76% 1-Year Est. Return
MWA
Midland Wealth Advisors Effingham, Illinois $1.94B AUM 14.31% 1-Year Est. Return

Finepoint Capital's Q2 2023 Portfolio in Review

As of Q2 2023, Finepoint Capital held 42 positions worth $289M, up 10% from $262M the previous quarter. Its ten largest holdings account for 61% of the portfolio.

Finepoint Capital's Q2 2023 filing shows 4 new, 2 increased, 14 reduced and 5 closed positions. Its largest new stake was Morphic Holding, Inc. Common Stock: 287,556 shares worth $16.5M. The largest sale was IVERIC bio, Inc. Common Stock, an estimated $17.6M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 99% a quarter earlier, followed by Technology.

  • Finepoint Capital's largest Q2 2023 buy was Morphic Holding, Inc. Common Stock: 287,556 shares worth $16.5M.
  • Finepoint Capital added most to Solid Biosciences in Q2 2023, an estimated $2.66M increase.
  • Finepoint Capital's biggest Q2 2023 reduction was Apellis Pharmaceuticals, cutting an estimated $3.62M.
  • Finepoint Capital fully exited IVERIC bio, Inc. Common Stock in Q2 2023, selling an estimated $17.6M.
  • Finepoint Capital's ten largest holdings make up 61% of its $289M portfolio in Q2 2023.
  • Finepoint Capital opened 4 new positions and closed 5 in Q2 2023.
  • Finepoint Capital's portfolio value rose 10% quarter-over-quarter to $289M.

Based on Finepoint Capital's 13F filing for Q2 2023, filed 11 Aug 2023.